item management s discussion and analysis of financial condition and results of operations 
summary in  bristol myers squibb surpassed billion in annual global sales and achieved record levels of sales and earnings 
all four of the company s business segments achieved record levels of sales  bringing the worldwide sales to billion  an increase over domestic sales  representing of worldwide sales  increased to billion  while international sales increased to billion 
sales growth resulted from a increase due to volume and a increase from changes in selling prices 
exchange rate fluctuations had no effect on worldwide sales  but did have an unfavorable effect of on international sales  primarily due to latin american and european currencies 
the company s most important product lines experienced double digit sales increases on a worldwide basis 
in fact  three products  pravachol  taxol paclitaxel and glucophage exceeded billion in sales  while six additional products exceeded over one half billion dollars in annual sales 
bristol myers squibb had product lines with more than million in annual sales  including with more than million in annual sales 
earnings before income taxes  excluding the special charge described below  increased to billion in net earnings  on this basis  increased to billion  basic and diluted earnings per share each increased to and  respectively 
over the past five years net earnings and diluted earnings per share  excluding special charges  have increased at compound annual growth rates of and  respectively 
in  the company reported diluted earnings per share growth over the prior year for each of the first three quarters and excluding the special charge  a growth rate in the fourth quarter 
in  consistent with the mission of the company to extend and enhance human life and develop the highest quality products  the company invested more than billion in research and development  a growth over the prior year and growing at an annualized rate of over the past five years 
this continuing investment has led to the discovery of innovative new products and the development of new indications for existing products including vanlev omapatrilat  a novel cardiovascular compound for the treatment of hypertension  which is the first antihypertensive ever to receive priority review from the us food and drug administration fda under the prescription drug user fee act  a glucophage glyburide product and glucophage xr extended release tablets  both for diabetes  vaniqa  a topical treatment for excessive facial hair in women  tequin  an advanced antibiotic for the treatment of multiple common infections  an easier to digest  enteric coated treatment form of videx for hiv aids  and taxol  for adjuvant treatment of node positive breast cancer 
bristol myers squibb s financial position remains strong 
at december   the company held almost billion in cash  time deposits and marketable securities 
cash provided by operating activities reached billion  the highest in the last years 
returns to shareholders included dividend distributions of billion and stock repurchases of billion 
dividends per common share were 
in  increasing from 
per share paid in the company has continued to lower its dividend payout ratio  which represents cash dividends paid per common share divided by diluted earnings per common share  that amounted to  and in  and  respectively  excluding the special charge 
in december  the company announced a dividend increase  the th consecutive year that dividends have increased  and expanded the share repurchase program authorization by an additional billion 
the indicated annual payment is 
per common share  a increase over  following a dividend increase in as further evidence of its strong financial position  bristol myers squibb is one of only seven us industrial companies to receive a triple a credit rating from both moody s and standard poor s 
net sales and earnings worldwide sales increased in to billion  compared with increases of and in and  respectively 
the consolidated sales growth in resulted from a increase due to volume  a increase due to changes in selling prices and no change due to foreign exchange rate fluctuations 
in  the increase in sales reflected a increase due to volume  a decrease due to foreign exchange rate fluctuations and a increase due to changes in selling prices 
in  the increase in sales reflected a increase due to volume  a decrease due to foreign exchange rate fluctuations and no changes overall from pricing activity 
domestic sales increased in both and  and in  while international sales increased in excluding foreign exchange  in excluding foreign exchange and in excluding foreign exchange 
in general  the businesses of the company s industry segments are not seasonal 
earnings before income taxes  excluding the charge described below  increased to  million from  million in net earnings on this basis increased to  million compared to  million in basic earnings per share increased to from in the prior year and diluted earnings per share increased to from 
net earnings margins  excluding the special charge  increased to in from in as described in the notes to the financial statements  in the fourth quarter of  the company recorded a special charge of million before taxes  million after taxes  or 
per diluted share  to augment the reserve for breast implant liability and for prescription drug pricing litigation  offset by expected insurance recoveries 
the breast implant component of the charge was million before taxes million of liability offset by insurance receivables of million  and the prescription drug pricing component was million before taxes 
as a result of the special charge  net earnings were  million  basic earnings per share were and diluted earnings per share were 
in  net earnings  excluding the special charge  were  million  a increase over basic earnings per share were and diluted earnings per share were  both increasing over net earnings margins  excluding the special charge  increased to in from in the effective income tax rate on earnings before income taxes was in  compared to in  excluding the special charge  and in the effective income tax rate has decreased since due to increased income in lower tax rate jurisdictions 
as described in note to the financial statements  in  the company acquired cal c tose  a leading nutritional milk modifier product in mexico 
in  the company acquired redmond products  inc  a leading hair care manufacturer in the us in  the company also acquired phytoervas  a line of premium retail hair care products in brazil  and dong a biotech co  ltd  a marketer and distributor of pharmaceutical products in south korea 
in  the company acquired abeefe sa  peru s largest pharmaceutical manufacturer and marketer 
the company also  in  acquired choco milk  mexico s leading milk based nutritional supplement  and sal de uvas picot  a leading effervescent antacid product in mexico 
as described in note to the financial statements  in the fourth quarter of  the company completed the sale of laboratori guieu  spa  an italian based gynecological  pediatric and dermatological products business 
in the first quarter of  the company divested its ban brand of anti perspirants and deodorants 
in the second quarter of  the company divested a s gea  a denmark based generic drug business  and hexachimie  a specialty chemical manufacturer based in france 
in the fourth quarter of  the company divested linvatec corporation  its arthroscopy and powered surgical instrument business 
in january  the company announced its intention to sell its matrix essentials  inc subsidiary  a manufacturer of professional hair care products sold exclusively through beauty salons 
expenses total costs and expenses  as a percentage of sales  improved over the last three years to in compared with in  excluding the special charge  and in as a percentage of sales  cost of products sold increased to in compared to in  principally due to sales growth of lower margin products from the oncology therapeutics network otn  a specialty distributor of anti cancer medicines and related products 
in  cost of products sold as a percentage of sales remained at the prior year s level of compared to in accordingly  the company has maintained its cost of goods sold as a percentage of sales consistently over the last three years  excluding its oncology distribution business 
advertising and promotion expenses increased over the prior year to  million in  primarily due to the continued support of pravachol  excedrin  glucophage and plavix in the medicines segment and for promotional campaigns related to existing products and new product launches in the beauty care and nutritional segments  including enfamil  boost  ultress  viactiv soft calcium chews and aussie land 
in  advertising and promotion expenses increased to  million from  million in as a percentage of sales  advertising and promotion expenses decreased to in from in and in  reflecting an improvement in the effectiveness of the advertising and promotion spending 
this decreasing trend is primarily due to reductions in direct to consumer advertising and increases in medical education efforts in the medicines segment 
marketing  selling and administrative expenses  as a percentage of sales  decreased to in from in and in this decreasing trend is a result of slower rates of increase in marketing  sales force and general administrative expenses as compared to revenue increases in the same period 
the company s investment in research and development totaled  million in  an increase of over  and an increase to in as a percentage of sales  from in and in this spending level reflects the company s commitment to research over a broad range of therapeutic areas and to clinical development of new products 
over the past five years  research and development expenses have increased at a compound annual growth rate of 
in  research and development spending dedicated to pharmaceutical products increased  and was of pharmaceutical sales compared to and in and  respectively 
in  eight regulatory approvals were obtained and dossiers were filed in the us most notably  in december  the company received fda approval for tequin  an advanced antibiotic for the treatment of multiple common infections  including those of the respiratory tract 
the company also received marketing clearance for new indications for several products  including in october  the use of taxol by injection for adjuvant treatment of node positive breast cancer following standard chemotherapy  and  in september  zerit and videx were approved for use as first line components of a combination antiretroviral therapy regimen for hiv infected patients 
in january  the company submitted a new drug application nda for videx didanosine a once daily  easier to digest  enteric coated form of videx 
in december  the company submitted a filing for vanlev omapatrilat in the us  european union and canada 
vanlev is the most clinically developed member of a new class of cardiovascular compounds developed for the treatment of hypertension 
in  the company also initiated filings to gain marketing approval for two antidiabetic drugs a new oral antidiabetic combination drug that leverages the benefits of two widely prescribed oral antidiabetic medications  glucophage metformin and glyburide  a well established sulfonylurea antidiabetic  and glucophage xr metformin hydrochloride extended release tablets  a once daily version of glucophage 
a nda for vaniqa  a topical treatment for excessive facial hair in women  was filed in september in  the company announced a number of research alliances  collaborations and commercialization agreements with other companies  including a development  commercialization and collaboration agreement with otsuka pharmaceutical co  ltd  for aripiprazole  a novel drug under study in phase iii trials as a treatment for schizophrenia  an alliance with millennium predictive medicine  inc  a subsidiary of millennium pharmaceutical  inc  in the emerging field of cancer pharmacogenomics  and a licensing agreement and research collaboration with oxigene  inc  to develop and commercialize combretastatin anti tumor vascular targeting agents 
the company recorded million and million in gains from the sale of businesses in and  respectively 
the company also recorded restructuring charges of million in and million in these restructuring charges consisted primarily of asset write downs and employee related costs related to the consolidation and closure of plants and facilities 
business segments all four of the company s business segments medicines  beauty care  medical devices and nutritionals reported sales increases during the year 
sales in the medicines segment pharmaceuticals and consumer medicines  which is bristol myers squibb s largest segment at of the total company  increased to  million in sales growth resulted from a increase due to volume and a increase from selling prices  offset by a decrease due to the effect of foreign exchange rate fluctuations 
domestic sales increased and international sales increased  excluding foreign exchange  primarily due to volume growth 
sales of pravachol  the company s largest selling product  increased to  million 
international sales increased excluding foreign exchange to million 
domestic sales increased to  million  reflecting intensifying competition 
the product s us market share leveled off at for the year 
in  the results of the prospective pravastatin pooling project  the largest statin drug analysis  found that pravachol consistently helps reduce the risk of recurrent coronary events in women  older patients and patients with diabetes 
the company also announced the launch of the pravastatin or atorvastatin evaluation and infection therapy  or prove it  trial  the first major clinical trial to compare the effects of pravachol versus lipitor in reducing the risk of heart attacks and other cardiac events 
this clinical trial also seeks to further examine the role of infection in atherosclerosis 
sales of taxol  the company s leading anti cancer agent  increased to billion as the product continued to benefit from increased use in ovarian  breast and non small cell lung cancer following standard chemotherapy 
in october  the fda approved the use of taxol by injection for adjuvant treatment of node positive breast cancer following standard chemotherapy 
there is no composition of matter patent for paclitaxel the active ingredient in taxol 
in the united states  the company is presently the only manufacturer and marketer of a product containing paclitaxel 
in and  the company filed several lawsuits alleging that a number of generic drug companies infringed its patents covering certain methods of administering paclitaxel when they filed abbreviated new drug applications seeking regulatory approval to sell paclitaxel 
the defendants have asserted that they do not infringe the company s patents and that these patents are invalid and unenforceable 
some defendants also asserted counterclaims seeking damages for alleged antitrust and unfair competition violation 
on january   the district court granted the company s motion to dismiss certain of the antitrust and unfair competition counterclaims 
the company s motion for summary judgment on the remaining antitrust and unfair competition counterclaims was denied on march  on february   the district court granted in part the generic companies summary judgment motions for invalidity by finding all claims of the company s patents in dispute invalid  except for claims limited to the treatment of ovarian cancer 
as a result of this ruling  the generic companies may obtain us food and drug administration approval to market paclitaxel solely for treatment of metastatic breast cancer after failure of combination chemotherapy 
the district court s opinion left for determination at trial the validity of the claims of the company s patents directed to the low dose  three hour administration of paclitaxel for ovarian cancer and denied the generic companies summary judgment motion arguing non infringement of the company s patents 
the company may pursue its appeal rights in the future 
the claims remaining in the lawsuits are currently scheduled for trial in may it is not possible at this time to make a reasonable assessment of the outcome of the remaining claims in these actions nor to reasonably estimate the impact on taxol sales or the amount of damages were the company not to prevail 
glucophage sales increased to  million 
glucophage  the leading branded oral medication for treatment of non insulin dependent type diabetes  had a market share of  up from in the prior year 
in may  the fda approved avandia in combination with glucophage for the treatment of type diabetes 
avandia is a product of smithkline beecham  and is being co promoted by bristol myers squibb in the us the hatch waxman legislation exclusivity for glucophage expires in september plavix  a platelet aggregation inhibitor for the reduction of stroke  heart attack and vascular death in atherosclerotic patients  reached sales of million for the year compared to million in the prior year 
sales of avapro  an angiotensin ii receptor blocker for the treatment of hypertension  increased to million 
avapro and plavix are cardiovascular products that were launched from the bristol myers squibb and sanofi sa joint venture 
sales of zerit and videx  the company s two anti retroviral agents  increased to million and to million  respectively 
zerit is the most commonly prescribed thymidine nucleoside reverse transcriptase inhibitor in hiv therapy in the us in  zerit and videx received regulatory approvals for use as first line components of a combination antiretroviral therapy regimen for hiv infected patients 
also  in november  the fda approved once daily dosing for videx 
sales of buspar  the company s novel anti anxiety agent  increased to million  while sales of serzone  a novel antidepressant  increased to million 
the exclusivity period for buspar expires in may sales of paraplatin  which is used in combination therapy for the treatment of ovarian cancer  increased to million 
sales of cefzil  an oral cephalosporin used in the treatment of respiratory infections and sinusitis  increased to million 
monopril  a second generation angiotensin converting enzyme ace inhibitor with once a day dosing  had increased sales of reaching million 
sales from the oncology therapeutics network  a specialty distributor of anti cancer medicines and related products  reached million for the year  an increase of over international sales of maxipime  a fourth generation injectable cephalosporin  increased to million 
effective january   dura pharmaceuticals  inc was appointed the exclusive domestic distributor for maxipime 
sales of excedrin remained at prior year levels of million 
in october  the fda expanded the excedrin migraine indication from the treatment of mild to moderate migraine pain to encompass the severe pain and associated symptoms of the full migraine syndrome 
sales of bufferin increased to million due to increased sales in japan  while sales of efferalgan  an effervescent analgesic sold primarily in france  increased to million 
sales of captopril  an ace inhibitor sold primarily under the trademark capoten  declined to million due to the loss of patent exclusivity in international markets 
in  medicines segment sales increased over levels 
increases in sales of pravachol  taxol  paraplatin  zerit  monopril  buspar  cefzil  glucophage  serzone  videx  avapro  plavix and excedrin were partially offset by decreases in sales of capoten 
the margin on earnings before taxes in the medicines segment improved to in from in  as reductions  as a percentage of sales  in sales force expenditures  advertising and promotion spending and general administrative expenses were partially offset by increases in cost of products sold 
in  the margin on earnings before taxes of remained at the prior year level as increases in research and development and sales force expenditures were offset by decreases in advertising and promotional spending and general administrative expenses 
sales in the beauty care segment increased in to  million  reflecting a increase due to volume  a increase due to pricing and a decrease due to foreign exchange rate fluctuations 
international sales increased excluding the effect of foreign exchange and domestic sales increased 
a softening in market demand in combination with other operating factors  including the introduction of a new demand management manufacturing system  slowed domestic shipments during the year 
the company s clairol division continues to be the number one hair products company in the us hair care product sales increased in  primarily due to sales of the herbal essences complete line of shampoos  conditioners  styling aids  body wash and facial care 
sales of the herbal essences line increased to million due to the launch of the herbal essences facial care line in the us and the launch of the herbal essences hair care line in japan  germany and brazil 
herbal essences is the number three brand in the total shampoo and conditioner market in the us  and is number four in body wash 
sales of daily defense increased to million following its launch into international markets 
sales of aussie products were million  an increase of over the prior year 
haircolor sales increased with increases in nice n easy of to million and natural instincts of to million  partially offset by a decrease of in hydrience to million 
in  sales in the beauty care segment increased from levels  primarily due to increased sales of hair care products  led by herbal essences 
the margin on earnings before taxes in the beauty care segment decreased to in  from in  primarily due to an increase  as a percentage of sales  in cost of products sold reflecting a change in product mix  higher levels of operating costs  and slower product shipments compared to the prior year 
increased promotional expenditures for new product introductions and support for existing products  including ultress and aussie land  also contributed to the decline 
in  the margin on earnings before taxes improved to from in primarily due to higher volumes and manufacturing efficiencies  partially offset by investment spending behind new product introductions 
sales in the medical devices segment increased to  million  excluding sales from a distribution agreement with the acquirer of zimmer s divested arthroscopy and powered surgical instrument business 
including the sales from the distribution agreement  medical devices sales increased  reflecting a increase due to volume  a increase due to the effect of foreign exchange and no effect from changes in selling prices 
domestic sales increased and international sales increased excluding the effect of foreign exchange 
worldwide sales of knee prosthetic joint replacements in the company s zimmer division increased and hip replacement sales increased 
the company s convatec division is the worldwide market share leader in ostomy and advanced wound care products 
convatec sales decreased to million while remaining at prior year levels excluding foreign exchange 
sales of ostomy products decreased and sales of wound care products were slightly below prior year levels 
in  worldwide sales in the medical devices segment  excluding the december divestiture of zimmer s arthroscopy and surgical powered instrument business  increased 
the margin on earnings before taxes in the medical devices segment improved to in from in  primarily due to a decrease in cost of products sold as a result of improved manufacturing processes 
the margin on earnings before taxes in the medical devices segment improved to in from in  due to decreases  as a percentage of sales  in other marketing and general administrative expenses  partially offset by increases in cost of products sold due to higher costs for products sold under a distribution agreement with the acquirer of linvatec 
sales in the nutritionals segment increased to  million  reflecting a increase due to volume  a decrease due to the effect of foreign exchange rate fluctuations primarily in latin america and a increase due to changes in selling prices 
international sales increased excluding the effect of foreign exchange  and domestic sales increased 
mead johnson continues to be the leader in the worldwide and us infant formula markets 
total infant formula sales increased to  million excluding foreign exchange 
sales of enfamil  the company s largest selling infant formula  increased to million worldwide 
adult consumer nutritional sales increased as a result of a increase in sales of boost  and million in sales of viactiv soft calcium chews launched in december in  worldwide sales of nutritionals decreased from levels  primarily due to decreases in infant formula sales partially offset by growth of nutramigen  lacto free  boost and choco milk 
the margin on earnings before taxes in the nutritionals segment decreased to in from in  primarily due to increased advertising and promotion expenditures for enfamil  boost and viactiv soft calcium chews 
the margin on earnings before taxes in the nutritionals segment improved to in from in due to decreases  as a percentage of sales  in cost of products sold  resulting from improved manufacturing efficiencies 
geographic areas bristol myers squibb products are available in virtually every country in the world  its largest markets are the us  france  japan  germany and canada 
sales in the united states  net of inter area sales  increased in sales in the medicines and beauty care segments comprised and  respectively  of the region s sales 
products with strong growth in the region included glucophage  taxol  enfamil  buspar  plavix  paraplatin and avapro 
the margin on earnings before taxes decreased to in from in primarily due to increases  as a percentage of sales  in cost of products sold 
in  sales in the united states increased  net of inter area sales  primarily due to growth of products from the medicines segment including glucophage  taxol  pravachol and hair care products from the beauty care segment 
the margin on earnings before taxes increased to in from in primarily due to decreases  as a percentage of sales  in cost of products sold  advertising and general administrative expenses 
sales in europe  mid east and africa  net of inter area sales  increased excluding foreign exchange 
the medicines segment comprised nearly of sales in the region 
products with strong growth in the region included pravachol  taxol  plavix  avapro and daily defense 
increases in sales of these products were partially offset by decreases in sales of ostomy supplies and of capoten  due to the loss of exclusivity and generic competition 
the margin on earnings before taxes increased to in from in  primarily due to improved sales force effectiveness as evidenced by lower sales force expense  as a percentage of sales  and a decrease in promotional expenses 
in  sales in europe  mid east and africa  net of inter area sales  increased excluding foreign exchange  due to sales growth of products  including taxol  zerit  pravachol and herbal essences 
these increases were partially offset by decreases in sales of capoten due to loss of exclusivity 
the margin on earnings before taxes decreased to in from in due to increases  as a percentage of sales  in promotional expenses 
sales in other western hemisphere countries  net of inter area sales and excluding foreign exchange  increased in the medicines and beauty care segments comprised nearly and  respectively  of the region s sales 
including foreign exchange  sales decreased primarily resulting from decreases in sales of capoten and pravachol  partially offset by growth in herbal essences  enfamil  daily defense  avapro and plavix 
the margin on earnings before taxes decreased to in from in as a result of the currency devaluation in brazil and regional economic downturns 
in  sales in other western hemisphere countries  net of inter area sales  increased excluding foreign exchange  due to the introduction of herbal essences and choco milk to the region 
the margin on earnings before taxes decreased to in from in  reflecting increases  as a percentage of sales  in cost of products sold 
sales in the pacific region  net of inter area sales  increased in excluding foreign exchange 
the favorable effect from foreign exchange was primarily experienced in japan 
the medicines and nutritionals segments comprised and  respectively  of the region s sales 
products with strong growth included bufferin  taxol  herbal essences and paraplatin 
taxol sales improved over the prior year following the japanese ministry of health and welfare clearance of new indications for taxol as a treatment for breast and non small cell lung cancers 
in  margin on earnings before taxes increased to primarily due to a decrease  as a percentage of sales  in advertising and promotion spending 
as a result of economic downturns and unfavorable fluctuations in exchange rates  earnings before taxes in the pacific region were minimal in and sales  net of inter area sales  decreased 
excluding foreign exchange  sales in increased as a result of increases in taxol and herbal essences  partly offset by decreases in infant formulas and capoten 
financial instruments cash and cash equivalents  time deposits and marketable securities totaled almost billion at december   compared to billion and billion at december  and  respectively 
working capital continued to improve in with billion at december   compared to billion and billion at december  and  respectively 
cash and cash equivalents  time deposits and marketable securities  and the conversion of other working capital items are expected to fund near term operations of the company 
the company is exposed to market risk due to changes in currency exchange rates 
to reduce this risk  the company enters into certain derivative financial instruments  where available on a cost effective basis  to hedge its underlying economic exposure 
these instruments also are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets 
it is the company s policy to hedge certain underlying economic exposures to reduce foreign exchange risk 
derivative financial instruments are not used for trading purposes 
gains and losses on hedging transactions are offset by gains and losses on the underlying exposures being hedged 
foreign exchange option contracts and  to a lesser extent  forward contracts are used to hedge anticipated transactions 
the company s primary foreign currency exposures in relation to the us dollar are the european currencies and the japanese yen 
the table below summarizes the company s outstanding foreign exchange option contracts as of december  the fair value of option contracts  which will change over time  is estimated based on currency rates and other relevant market factors 
the fair value of option contracts should be viewed in relation to the fair value of the underlying hedged transactions and the overall reduction in exposure to adverse fluctuations in foreign currency exchange rates 
weighted average dollars in millions strike notional carrying fair price amount value value maturity option contracts purchased right to sell euro mexican peso canadian dollar british pound brazilian real australian dollar greek drachma swiss franc other currencies various right to buy japanese yen british pound at december   the company held right to sell option contracts with an aggregate notional amount  carrying value and fair value of  million  million and million  respectively 
these contracts primarily related to option contracts with the right to sell french francs and deutsche marks 
other contracts at december  included right to buy option contracts  primarily to buy japanese yen for us dollars and british pounds for deutsche marks  as well as other option contracts  that include the right to buy and sell several currencies 
these contracts had an aggregate notional amount  carrying value and fair value of million  million and million  respectively 
the company maintains cash and cash equivalents  time deposits and marketable securities with various financial institutions 
these financial institutions are located primarily in the us and europe 
company policy is designed to limit exposure to any one financial institution 
recently issued accounting standards in june  the financial accounting standards board issued statement of financial accounting standards no 
 accounting for derivative instruments and hedging activities deferral of the effective date of fasb statement no 
this statement defers the effective date of sfas  accounting for derivative instruments and hedging activities  to fiscal years beginning after june  this statement requires that companies recognize all derivatives as either assets or liabilities on the balance sheet and measure these instruments at fair value 
the company will adopt this statement on january  and is currently evaluating its impact on the company s existing accounting policies and financial reporting disclosures 
euro conversion on january   certain members of the european union established fixed conversion rates between their existing currencies and the european union s common currency  known as the euro 
it is planned that by july   the participating countries will withdraw all currencies and exclusively use the euro 
the company has committed resources to conduct assessments and to take corrective actions to ensure it is prepared for the introduction of the euro 
the company is actively addressing the many areas involved with the introduction of the euro  including information management  finance  legal and tax 
this review includes the conversion of information technology  business and financial systems  evaluating currency risk and the effect on the company s financial instruments  as well as the impact on the pricing and distribution of company products 
the company believes the effect of the introduction of the euro  as well as any related cost of conversion  will not have a material impact on the results of operations  financial condition and cash flows 
financial position cash and cash equivalents  time deposits and marketable securities at december  were denominated primarily in us dollar instruments with near term maturities 
the average interest yield on cash and cash equivalents was at december   while interest yields on time deposits and marketable securities averaged at december  short term borrowings and long term debt at december  are denominated primarily in us dollars  however  the company had million of commercial paper outstanding at december  this commercial paper has original maturities not exceeding days and is denominated in euros and us dollars 
also included is japanese yen long term debt of million 
internally generated cash provided by operations was billion in  billion in and billion in cash provided by operations continued to be the company s primary source of funds to finance operating needs and expenditures for new plants and equipment 
as part of the company s ongoing commitment to improve plant efficiency and maintain superior research facilities  the company has invested billion in capital expansion over the past three years 
cash flow from operations also included product liability payments  net of insurance recoverable receipts of million in  million in and million in cash provided by operations also was used over the past three years to pay dividends of billion  to finance billion of the company s share repurchase program and to fund business acquisitions at a cost of million 
the company s share repurchase program authorizes the company to purchase common stock from time to time in the open market or through private transactions as market conditions permit 
during  the company purchased million shares of common stock at a cost of billion  bringing the total shares acquired since the program s inception to million 
in december  the company announced a billion increase in the stock repurchase program authorization 
during the past three years  the company has repurchased million shares at a cost of billion 
in may  at the annual meeting of stockholders  the stockholders approved the increase in the number of shares of common stock authorized to billion shares 
employment levels of  at december essentially remained at prior year levels of  sales per employee improved to thousand in from thousand in and thousand in return on stockholders equity improved over the last three years and was in  in  excluding the special charge  and in forward looking information certain statements in this form k annual report may constitute forward looking statements within the meaning of the private securities litigation reform act of these statements involve a number of risks  uncertainties and other factors that could cause actual results to differ materially from expected and historical results 
certain factors that may affect the company s operations and prospects are discussed in exhibit to this form k annual report 

